GlassScriptPhysician profile
Lewis A Levy
NPI 1750372702
$10,746.17
in general payments reported to CMS, 2019-2025
69 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $945 · 2021: $1,332 · 2022: $1,395 · 2023: $1,714 · 2024: $2,194 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $482.40 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $470.25 | 2019-2024 | Ztlido |
| Eisai INC. | $450.09 | 2023-2025 | |
| Ucb, INC. | $429.23 | 2019-2025 | Rystiggo, Fintepla, Briviact |
| Biogen, INC. | $424.46 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $383.44 | 2022-2025 | Vyvgart |
| Lilly USA, LLC | $367.50 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Otsuka America Pharmaceutical, INC. | $352.06 | 2023-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $345.50 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Neurocrine Biosciences, INC. | $307.34 | 2021-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $306.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $304.39 | 2019-2022 | |
| Genzyme Corporation | $296.29 | 2019-2023 | |
| Amgen INC. | $288.96 | 2019-2025 | Uplizna |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.